Welcome to our dedicated page for Transmedics Group SEC filings (Ticker: TMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TransMedics Group, Inc. filings document a Nasdaq-listed medical technology company built around the Organ Care System, National OCS Program and related transplant logistics services for lung, heart and liver transplantation. Its 8-K reports furnish operating results, guidance, tax valuation allowance disclosures and business drivers such as OCS case utilization, logistics revenue and aircraft assets.
Other filings cover material agreements, including headquarters facilities and completed aircraft acquisitions, as well as executive transitions, compensatory arrangements, inducement awards and proxy-governance matters. The company's disclosures also describe its common stock listing, board and shareholder voting matters, executive compensation, clinical program updates and FDA-related device disclosures.
Lovell Stephanie reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director Stephanie Lovell received an equity award in the form of restricted stock units. On May 20, 2026, she was granted 2,922 shares of common stock at a price of $0.00 per share as a compensation-related award, not an open-market purchase. Each restricted stock unit represents a contingent right to receive one share of TransMedics common stock. Following this grant, Lovell directly holds 5,788 shares of the company’s common stock.
Weill David reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director David Weill reported an equity compensation grant of 2,922 shares of common stock in the form of restricted stock units. Each RSU represents a contingent right to receive one share of common stock, with no cash paid per share. Following this award, Weill directly holds 15,056 shares of TransMedics common stock, reflecting a routine compensation-related increase in his ownership rather than an open-market purchase.
RAINES MERILEE reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group director Merilee Raines received an equity grant of 2,922 restricted stock units (RSUs) on common stock. These RSUs are a form of stock-based compensation, with each unit representing the right to receive one TransMedics common share. Following this award, Raines directly holds 6,981 common shares.
Gunderson Thomas J. reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director Thomas J. Gunderson received an equity award of 2,922 restricted stock units. These RSUs were granted at no cash cost and each unit represents the right to receive one share of common stock. Following this grant, he directly holds 6,981 shares and RSUs in total, reflecting routine, compensation-related ownership rather than an open-market purchase or sale.
Basile Edward M reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director Edward M. Basile received a grant of 2,922 shares of common stock in the form of restricted stock units. The award was made at no cash cost per share and is a form of equity compensation. Following this grant, Basile directly holds 5,788 shares of the company’s common stock, showing his stake has increased through stock-based awards rather than open-market purchases or sales.
TOBIN JAMES R reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director James R. Tobin reported an equity award rather than an open-market trade. He received 2,922 restricted stock units, each representing a contingent right to one share of common stock at no cash cost. Following this grant, he holds 6,981 shares directly, in addition to indirect holdings reported as 18,000 shares held by The Tobin 2024 Family Trust and 155,146 shares held by the James R. Tobin 2012 Trust.
TransMedics Group director Edwin Kania reported a new equity award. On May 20, 2026, he received 2,922 restricted stock units, each representing one share of common stock. This is a compensation-related grant at $0.00 per share, not an open‑market purchase.
After the grant, Kania directly holds 263,732 common shares and indirectly holds 46,142 shares through Kania 2021 GRAT B. The filing shows no sales or option exercises, so the activity reflects an incremental increase in his overall ownership stake.
TransMedics Group, Inc. reported that company officer Matthew S. Forsyth received equity compensation on May 19, 2026. He was granted 15,409 restricted stock units, each representing one share of common stock, and a stock option for 23,171 shares of common stock at an exercise price of $66.13 per share. The option expires on March 9, 2036 and vests 25% on March 9, 2027, with the remainder vesting in equal monthly installments over the following three years, subject to continued service. These awards increase his direct equity stake and align his compensation with the company’s share performance.
TransMedics Group, Inc. reported the results of its 2026 Annual Meeting of Shareholders. Shareholders elected eight directors, including Waleed Hassanein, M.D. and James R. Tobin, to serve until the 2027 annual meeting or until successors are elected.
They approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 22,871,647 votes in favor, 1,161,181 against and 30,895 abstentions. Shareholders also approved an amendment to the Amended and Restated TransMedics Group, Inc. 2019 Stock Incentive Plan, with 17,265,369 votes for and 6,758,882 against.
In addition, shareholders ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,030,696 votes for, 648,359 against and 17,653 abstentions.
TransMedics Group, Inc. reported net revenue of $173.9 million for the quarter ended March 31, 2026, up from $143.5 million a year earlier, driven mainly by strong U.S. liver transplant activity. U.S. OCS liver revenue rose to $139.0 million from $108.7 million, while heart and lung revenue were roughly flat to down slightly.
Gross profit increased to $101.2 million, but higher research and development and selling, general and administrative expenses reduced income from operations to $13.3 million from $27.4 million. Net income declined to $7.3 million (diluted EPS $0.20) from $25.7 million (diluted EPS $0.70).
The company ended the quarter with $480.2 million in cash and restricted cash and total assets of $1.43 billion, reflecting recognition of a large $334.5 million finance lease right-of-use asset for its new Somerville, Massachusetts headquarters. Operating cash flow improved to $24.5 million, while capital expenditures were $36.7 million.